Ionis Pharmaceuticals (IONS) EBT (2009 - 2026)

Ionis Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at -$92.3 million for Q1 2026.

• On a quarterly basis, EBT rose 37.13% year-over-year to -$92.3 million in Q1 2026; TTM through Mar 2026 was -$325.1 million, a 30.06% increase from a year earlier, with the FY2025 full-year figure at -$379.6 million, up 17.61% from the prior year.
• EBT climbed to -$92.3 million in Q1 2026 per IONS's latest filing, from -$227.9 million in the prior quarter.
• Across five years, EBT topped out at $331.9 million in Q4 2023 and bottomed at -$227.9 million in Q4 2025.
• The 5-year median for EBT is -$102.9 million (2022), against an average of -$70.0 million.
• Biggest YoY gain for EBT was 848.79% in 2023; the steepest drop was 201.46% in 2023.
• Year by year, EBT stood at -$44.3 million in 2022, then soared by 848.79% to $331.9 million in 2023, then plunged by 132.44% to -$107.7 million in 2024, then slumped by 111.65% to -$227.9 million in 2025, then surged by 59.5% to -$92.3 million in 2026.
• Per Business Quant, the three latest IONS EBT figures stand at -$92.3 million (Q1 2026), -$227.9 million (Q4 2025), and -$128.4 million (Q3 2025).